Papers
3
Total Citations
191
H-Index
3
About
William Hsu is a leading researcher at the intersection of urologic oncology and advanced medical imaging, with a primary focus on improving the diagnosis, treatment planning, and cost-effectiveness of care for prostate cancer. His work is distinguished by its dual commitment to clinical outcomes and healthcare economics. Hsu made a significant contribution with his highly cited 2015 study (144 citations) that applied time-driven activity-based costing (TDABC) to quantify the long-term costs of treating localized, low-risk prostate cancer, providing crucial data for value-based care decisions. He is also a key investigator in the use of multiparametric 3 Tesla magnetic resonance imaging (MRI) and the PI-RADS scoring system. His research has demonstrated that PI-RADS version 2 scores can predict adverse oncologic outcomes in Gleason 3+4 disease, and he has identified volumetric MRI predictors of biochemical recurrence following robotic-assisted radical prostatectomy, correlating these findings with whole-mount histopathology. By linking advanced imaging biomarkers with pathological and economic realities, Hsu’s work directly informs more personalized, efficient, and effective management strategies for prostate cancer patients.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3